News & Videos - HUTCHMED (CHINA) LIMITED ORD USD0.10

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HUTCHMED (China) Limited - HCM PR Newswire NEW YORK, May 30, 2022 NEW YORK , May 30, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HUTCHMED ( China ) Limited ("Hutchmed" or the "Company") (NASDAQ: HCM). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Hutchmed and certain of its...

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HUTCHMED (China) Limited (“HUTCHMED” or “the Company”) (NASDAQ: HCM ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. HUTCHMED announced on May 2, 2022, that the FDA had rejected the Company’s application for...

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HUTCHMED (China) Limited (“HUTCHMED” or “the Company”) (NASDAQ: HCM ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. HUTCHMED announced on May 2, 2022, that the FDA had rejected the Company’s application for...

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of HUTCHMED (China) Limited (NASDAQ: HCM) resulting from allegations that HUTCHMED may have issued materially misleading business information to the investing public. SO WHAT: If you purchased HUTCHMED securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HUTCHMED (China) Limited - HCM PR Newswire NEW YORK, May 3, 2022 NEW YORK , May 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HUTCHMED ( China ) Limited ("Hutchmed" or the "Company") (NASDAQ: HCM). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Hutchmed and certain of its...

LONDON, UK / ACCESSWIRE / November 29, 2019 / Hutchison China MediTech (NASDAQ:HCM) has announced that Elunate (fruquintinib capsules) have been included in China's National Reimbursement Drug List (NRDL) by the National Healthcare Security Administration (NHSA). Although expected, this is a huge positive as from 1 January 2020 Elunate will be available in all state-run hospital pharmacies and patients on NHSA insurance schemes will be reimbursed. HCM's innovative oncology assets are making...

LONDON, UK / ACCESSWIRE / July 5, 2019 / Hutchison China MediTech (HCM) has announced positive data that key late-stage asset surufatinib met the primary endpoint of PFS in non-pancreatic at the Phase III interim analysis. This translates to an earlier than expected China NDA submission (H219) and the potential launch of HCM's first un-partnered asset (early 2021). In China, partner Lilly has launched Elunate (fruquintinib) capsules. Early sales look promising and its potential inclusion on the...